title: [What have we learned from converting enzyme inhibitors on renin-angiotensin system?].
abstract: Angiotensin-converting-enzyme (ACE) inhibitors are now widely used to treat patients with high blood pressure or heart failure. The favourable results obtained with these inhibitors of the renin-angiotensin system suggest that angiotensin II has a noxious effect on the development and/or course of these diseases. ACE inhibitors are usually well tolerated. Their most severe side-effects are mostly foreseeable and therefore avoidable. Chronic blockade of the renin-angiotensin system increasingly seems to be a good therapeutic approach to the protection of the vital organs.
authors.affiliation: Division d'hypertension, centre hospitalier universitaire Vaudois, Lausanne, Suisse.
authors.forename: B
authors.initials: B
authors.lastname: Waeber
authors.forename: J
authors.initials: J
authors.lastname: Nussberger
authors.forename: H R
authors.initials: HR
authors.lastname: Brunner
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D007703:Peptidyl-Dipeptidase A / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D007703:Peptidyl-Dipeptidase A
vernacular_title: Qu'est-ce que les inhibiteurs de l'enzyme de conversion nous ont appris sur le système rénine-angiotensine?